Literature DB >> 22133616

Vav1 in differentiation of tumoral promyelocytes.

Valeria Bertagnolo1, Federica Brugnoli, Silvia Grassilli, Ervin Nika, Silvano Capitani.   

Abstract

The multidomain protein Vav1, in addition to promote the acquisition of maturation related properties by normal hematopoietic cells, is a key player in the ATRA- and PMA-induced completion of the differentiation program of tumoral myeloid precursors derived from APL. This review is focussed on the role of Vav1 in differentiating promyelocytes, as part of interconnected networks of functionally related proteins ended to regulate different aspects of myeloid maturation. The role of Vav1 in determining actin cytoskeleton reorganization alternative to the best known function as a GEF for small G proteins is discussed, as well as the binding of Vav1 with cytoplasmic and nuclear signaling molecules which provides a new perspective in the modulation of nuclear architecture and activity. In particular, new hints are provided on the ability of Vav1 to determine the nuclear amount of proteins implicated in modulating mRNA production and stability and in regulating the ATRA-dependent protein expression also by direct interaction with transcription factors known to drive the ATRA-induced maturation of myeloid cells. The reviewed findings summarize the major advances in the understanding of additional, non conventional functions connected with the vast interactive potential of Vav1.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133616     DOI: 10.1016/j.cellsig.2011.11.017

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

Review 1.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

2.  A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.

Authors:  Silvia Grassilli; Ervin Nika; Elisabetta Lambertini; Federica Brugnoli; Roberta Piva; Silvano Capitani; Valeria Bertagnolo
Journal:  Cell Oncol (Dordr)       Date:  2016-08-01       Impact factor: 6.730

3.  Clinical significance and prognostic value of Vav1 expression in Non-small cell lung cancer.

Authors:  Yao Qi; Fan-Ming Kong; Qi Deng; Jing-Yi Li; Rui Cui; Ye-Di Pu; Qiong-Li Zhai; Ying-Jie Jia; Yu-Ming Li
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

4.  Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype.

Authors:  Silvia Grassilli; Federica Brugnoli; Stefano Cairo; Nicoletta Bianchi; Jean-Gabriel Judde; Valeria Bertagnolo
Journal:  J Pers Med       Date:  2022-06-17

5.  The Salmonella Typhimurium effector SteC inhibits Cdc42-mediated signaling through binding to the exchange factor Cdc24 in Saccharomyces cerevisiae.

Authors:  Pablo Fernandez-Piñar; Ainel Alemán; John Sondek; Henrik G Dohlman; María Molina; Humberto Martín
Journal:  Mol Biol Cell       Date:  2012-09-26       Impact factor: 4.138

6.  Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts.

Authors:  Holly A Jensen; Rodica P Bunaciu; Christopher N Ibabao; Rebecca Myers; Jeffrey D Varner; Andrew Yen
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

7.  High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process.

Authors:  Silvia Grassilli; Federica Brugnoli; Rossano Lattanzio; Cosmo Rossi; Letizia Perracchio; Marcella Mottolese; Marco Marchisio; Maria Palomba; Ervin Nika; Pier Giorgio Natali; Mauro Piantelli; Silvano Capitani; Valeria Bertagnolo
Journal:  Oncotarget       Date:  2014-06-30

Review 8.  Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.

Authors:  Shulamit Katzav
Journal:  Oncotarget       Date:  2015-10-06

9.  Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.

Authors:  Federica Vezzali; Silvia Grassilli; Elisabetta Lambertini; Federica Brugnoli; Simone Patergnani; Ervin Nika; Roberta Piva; Paolo Pinton; Silvano Capitani; Valeria Bertagnolo
Journal:  J Cell Mol Med       Date:  2018-03-13       Impact factor: 5.310

10.  Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome.

Authors:  Silvia Grassilli; Federica Brugnoli; Rossano Lattanzio; Marco Marchisio; Letizia Perracchio; Mauro Piantelli; Alberto Bavelloni; Silvano Capitani; Valeria Bertagnolo
Journal:  Mol Oncol       Date:  2018-05-16       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.